Weight stigma—often referred to as fatphobia or weight bias—pervades many aspects of life, from healthcare and employment to everyday social interactions. This bias assumes that larger bodies are less desirable, less disciplined, or even less worthy. Meanwhile, a new class of medications known as GLP-1 agonists (including brand names like Ozempic and Wegovy) has made significant weight loss more attainable for many. These drugs, originally developed to treat diabetes, have been repurposed as potent weight-loss aids, leading to dramatic transformations in patients’ bodies​

The “GLP-1 revelation” refers to how these rapid weight changes have exposed the extent of fatphobia ingrained in U.S. culture. When individuals shed pounds quickly via weekly injections of semaglutide (the active ingredient in Ozempic)​, they often find that society treats them very differently—revealing biases that were always there. This podcast delves into personal stories from Americans who have experienced this shift, examines psychological impacts of fatphobia, and presents data on the social and economic disparities it causes in the U.S. It also contrasts treatment people get before and after GLP-1-induced weight loss, illustrating what these changes say about American culture’s deep-seated biases.

How can a drug for weight loss and diabetes cure addiction to substances?  

Researchers and patients of GLP-1 medications are seeing significant reductions on addiction to drugs and alcohol. 

Join us as we do a deep dive on this promising research that could save hundreds of thousands of lives.

This is the official podcast of the patient led community GLP-1 Tribe - https://glp1tribe.com/

This episode serves as a patient guide for individuals using GLP-1 medications, explaining their mechanisms and benefits for managing type 2 diabetes and promoting weight loss. It emphasizes nutritional strategies focusing on protein and fiber, recommends creating a sustainable fitness plan with both aerobic and strength training, and discusses the potential role of supplements to address nutritional gaps and side effects. The guide also highlights the importance of lifestyle adjustments, including stress management, quality sleep, and regular medical check-ups, while setting realistic expectations for treatment success and sharing real-world insights from other users. Ultimately, it aims to empower patients to optimize their health journey with GLP-1 medications through informed choices and comprehensive self-care.

Learn more about GLP-1 at the patient led community GLP1 Tribe
https://glp1tribe.com/

We introduce our podcast at GLP-1 Tribe with an overview of everything people considering taking GLP-1 medications need to know.  And why are millions of Americans taking these medicines?  GLP-1 receptor agonists, a class of medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), explaining their mechanisms of action, approved uses for type 2 diabetes and weight management, and their history and development. They discuss the increasing prevalence of their use, typical effectiveness in clinical trials for blood sugar control and weight loss, common and serious side effects and risks, and findings from long-term studies. The sources also compare these medications, address cost and insurance coverage, and emphasize the importance of informed decision-making in consultation with healthcare providers regarding their use.

Learn more about GLP-1 at the patient led community GLP1 Tribe
https://glp1tribe.com/